← Back to Search

Neuromodulation

Brain Stimulation for Suicide Risk (ENACTS Trial)

N/A
Recruiting
Led By Casey S Gilmore, PhD
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
are unable to provide informed consent as determined by the Modified Dysken Tool
have contraindications for tDCS (history of seizures, metallic cranial plates/screws or implanted device, history of eczema on scalp)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Summary

This trial tests a short-term treatment using a gentle brain treatment and exercises to help Veterans improve decision-making and reduce suicidal thoughts and behaviors.

Who is the study for?
This trial is for veterans currently in the MVAHCS Inpatient Psychiatric Unit who are at high risk of suicide, either screened positive on the VA's risk evaluation or attempted suicide within the last year. Participants must be able to complete tasks and have a smartphone. Those with seizure history, metal in their head, severe skin conditions on the scalp, involuntary commitment, inability to consent, or significant cognitive impairment cannot join.
What is being tested?
The ENACTS study tests a five-day intervention combining transcranial direct current stimulation (tDCS) with executive function training for veterans at high suicide risk. The goal is to see if this can reduce future suicidal behavior and improve quality of life. Participants will receive either active tDCS or a sham (placebo) version as part of the study.
What are the potential side effects?
While not explicitly listed here, common side effects of tDCS may include mild tingling, itching or discomfort at the electrode sites during stimulation; headache; fatigue; nausea; and insomnia.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am able to understand and agree to the study's requirements.
Select...
I don't have seizures, metal in my head, or scalp eczema.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Intervention Acceptability
Recruitment Feasibility
Secondary study objectives
Groton Maze Task
NIH Quality of Life questionnaire
UPPS-P Impulsive Behavior scale

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active tDCSExperimental Treatment1 Intervention
Participants will receive 10 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over left frontal cortex, cathode over right frontal cortex; 2 mAmps for 20 minutes).
Group II: Sham tDCSPlacebo Group1 Intervention
Participants will receive 10 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Active Transcranial Direct Current Stimulation (tDCS)
2020
N/A
~160

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,647 Previous Clinical Trials
3,360,032 Total Patients Enrolled
41 Trials studying Suicide
7,165 Patients Enrolled for Suicide
Casey S Gilmore, PhDPrincipal InvestigatorMinneapolis VA Health Care System, Minneapolis, MN

Media Library

Active Transcranial Direct Current Stimulation (tDCS) (Neuromodulation) Clinical Trial Eligibility Overview. Trial Name: NCT05231213 — N/A
Suicide Research Study Groups: Active tDCS, Sham tDCS
Suicide Clinical Trial 2023: Active Transcranial Direct Current Stimulation (tDCS) Highlights & Side Effects. Trial Name: NCT05231213 — N/A
Active Transcranial Direct Current Stimulation (tDCS) (Neuromodulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05231213 — N/A
~7 spots leftby Mar 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top